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schizophrenia guideline recommendations
Huajie Jin, Paul Tappenden, James H. MacCabe, Stewart Robinson, Paul McCrone and Sarah Byford
Background
Discrepancies between the National Institute for Health and Care
Excellence (NICE) schizophrenia guideline recommendations
and current clinical practice in the UK have been reported.
Aims
We aim to assess whether it is cost-effective to improve
adherence to the NICE schizophrenia guideline recommenda-
tions, compared with current practice.
Method
A previously developed whole-disease model for schizophrenia,
using the discrete event simulation method, was adapted to
assess the cost and health impacts of adherence to the NICE
recommendations. Three scenarios to improve adherence to the
clinical guidelines were modelled: universal provision of cogni-
tive–behavioural therapy for patients at clinical high risk of
psychosis, universal provision of family intervention for patients
with first-episode psychosis and prompt provision of clozapine
for patients with treatment-resistant schizophrenia. The primary
outcomes were lifetime costs and quality-adjusted life-years
gained.
Results
The results suggest full adherence to the guideline recommen-
dations would decrease cost and improve quality-adjusted
life-years. Based on the NICE willingness-to-pay threshold of
£20 000–£30 000 per quality-adjusted life-year gained, prompt
provision of clozapine for patients with treatment-resistant
schizophrenia results in the greatest net monetary benefit, fol-
lowed by universal provision of cognitive–behavioural therapy
for patients at clinical high risk of psychosis, and universal pro-
vision of family intervention for patients with first-episode
psychosis.
Conclusions
Our results suggest that adherence to guideline recommenda-
tions would decrease cost and improve quality-adjusted life-
years. Greater investment is needed to improve guideline
adherence and therefore improve patient quality of life and
realise potential cost savings.
Keywords
Guideline adherence; schizophrenia; economics; cognitive–
behavioural therapy; clozapine.
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For people who are at risk of or diagnosed with schizophrenia, the
key interventions recommended by the National Institute for
Health and Care Excellence (NICE) include antipsychotic medica-
tions, cognitive–behavioural therapy (CBT) and family interven-
tion.1 However, discrepancies between the NICE schizophrenia
guideline recommendations and current clinical practice in the
UK have been reported. A recent national audit2 suggested that
CBT and family interventions were only offered to <50% of eligible
patients. It is suggested that this treatment gap might be largely
related to underinvestment in services.3 In addition, there is
evidence that despite the NICE schizophrenia guideline recommen-
dation that clozapine should be offered to patients with treatment-
resistant schizophrenia (TRS) with no delay, in clinical practice,
there is a 4-year delay in providing clozapine to people with
TRS.4 This might be caused by clinicians’ concerns about cloza-
pine-induced neutropenia and agranulocytosis, and the resources
required for constant haematologic monitoring.
There is little evidence regarding the cost-effectiveness of prac-
tice guideline adherence for severe mental health disorders includ-
ing schizophrenia. The closest example is a USA study that
compared the clinical outcomes and healthcare costs between
patients who received the Texas Medication algorithm-guided
medication management or usual care, for patients with severe
mental health disorders.5However, the Texas Medication algorithm
only covers pharmacological interventions and does not cover the
full range of interventions available for these disorders. This study
was therefore conducted in an effort to determine the cost-effective-
ness of improved adherence to a number of recommendations from
the NICE schizophrenia guideline, compared with current practice
in the UK. Both pharmacological interventions (i.e. antipsychotic
medications) and non-pharmacological interventions (e.g. CBT
and family intervention) recommended by NICE were assessed.
A recent systematic review of existing economic models in
schizophrenia found that >80% of existing models assessed
antipsychotic medications, whereas there were few models for
non-pharmacological interventions.6 To our knowledge, this
schizophrenia whole-disease model (WDM)7 is the only model
that covers both pharmacological and non-pharmacological inter-
ventions in the UK. In addition, the schizophrenia WDM was
populated with high-quality input data and has been extensively
checked and validated. Therefore, the schizophrenia WDM was
used to simulate the impacts of guideline adherence in this study.
Method
The reporting of this study followed the recommendations of the
Consolidated Health Economic Evaluation Reporting Standards
statement.8 Per the Common Rule, ethical approval and informed
patient consent were not required given that this is a modelling
study with no direct patient contact or influence on patient care dir-
ectly related to this work.Within the current study, the schizophrenia
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WDM was adapted to conduct a cost–utility analysis (CUA) to
compare the cost-effectiveness of full adherence to the NICE schizo-
phrenia guideline recommendations with current practice. CUA is
one of the most widely used types of economic evaluation in health-
care. Within a CUA, effectiveness is measured in terms of generic
‘healthy years’, such as quality-adjusted life-years (QALYs). QALYs
are generic measures of disease burden, which attempt to combine
both the quality and the quantity of a person’s life in response to a
disease or a treatment for disease. One QALY is equivalent to a
year in perfect health. To calculate QALYs, duration of life (survival)
is weighted using ‘utilities’, which are estimated with appropriate
preference-based measures of health-related quality of life
(HRQoL).9 These measures of HRQoL are commonly anchored at
1 (perfect or best imaginable health) and 0 (death), with negative
values possible in some scales to indicate a health state that is
valued as less preferable than death. For example, if a patient has a
utility of 0.5 over a period of 10 years, they would accrue 5
QALYs. As recommended by NICE,10 a costing perspective of the
UK health and social care system was adopted.
Model structure
The schizophrenia WDM simulates the entire disease and treatment
pathways for people at clinical high risk of psychoses (CHR) or with a
diagnosis of psychosis or schizophrenia over a lifetime horizon.
Patients enter the model following referral to secondary mental
healthcare services for possible psychosis, and exit the model when
they die. A discrete event simulation model was developed with
SIMUL8 software (Simul8 Corporation, Glasgow, UK, professional
version 15.0 for Windows; see https://www.simul8.com/online/).
Discrete event simulation is a modelling method that simulates the
experience of each individual patient. The clinical course of each
patient is determined based on their characteristics, such as age,
family history, previous events (e.g. relapses) and previous treatments.
The structure of the schizophrenia WDM is presented in Fig. 1.
There are four modules within the WDM: specialist assessment
pathway (module A), CHR pathway (module B), psychosis pathway
(module C) and out-of-scope and death pathway (module D).
After entering the model through module A, patients are triaged
to different modules based on the assessment results: CHR (module
B), psychosis (module C) or not at risk of psychosis (module D).
Patients at module B can move to module D (if they die) or
module C (if they develop psychosis). Patients at module C cannot
move to module B, but they can move to module D if they receive
a non-schizophrenia diagnosis or die. Patients at module D cannot
move to other modules. Within each module, the intervention
received by specific patients depends on three factors: their disease
status (not at risk of psychosis, CHR, first-episode psychosis (FEP),
subsequent acute psychosis or subsequent non-acute psychosis),
availability of the intervention and patients’ acceptance of non-com-
pulsory interventions. In the model, it is assumed that patients may
refuse to take upCBT and/or family intervention. The prescription of
antipsychotic medications is assumed to be optional for patients with
FEP in a stable condition, and is compulsory for all the other patients
with psychosis. However, patients might discontinue their prescribed
antipsychotic medications for various reasons. In the WDM, discon-
tinuation of antipsychotic medications was modelled, and the
primary reason for discontinuing antipsychotic medication were
grouped into three mutually exclusive categories: inefficacy, intoler-
ance and non-adherence not otherwise specified. Patients who dis-
continue their antipsychotic medication because of inefficacy are
assumed to experience a relapse, and will be switched to a different
antipsychotic medication after their relapses have been managed.
Patients who discontinue their antipsychotic medication because of
intolerance will be switched to a different antipsychotic medication
without experiencing a relapse. Patients who discontinue anti-
psychotic medication because of non-adherence will no longer take
any antipsychotic medication until they experience relapses. After
managing relapse, those patients will either return to their previous
antipsychotic medication, if this is the first time that they discontinue
an oral antipsychotic medication because of non-adherence, or be
switched to a long-acting injectable antipsychotic medication, if
they have discontinued oral antipsychotic medications more than
once. A comprehensive description of themodel structure is reported
by Jin et al.7
Prioritisation of interventions for modelling
The NICE schizophrenia guideline recommended nine key inter-
ventions, including specialist mental health assessment, CBT,
family intervention, antipsychotic medication, rapid triage assess-
ment of acute psychosis by the crisis resolution and home treatment
team, rapid tranquilisation, monitoring and treatment for coexist-
ing conditions, and occupational and educational interventions.1
Because of data availability issues and resource constraints to this
study, it was not possible to model adherence to all interventions
recommended by the NICE schizophrenia guideline. Based on
importance and data availability, three interventions were priori-
tised for evaluation with the model: individual CBT for people at
CHR, family interventions for patients with FEP and oral clozapine
for patients with TRS. The most common reason for excluding an
intervention from this analysis was lack of evidence about the clin-
ical and cost impacts of the intervention. A list of interventions
excluded are listed in Supplementary File 1, Section 1 available at
https://doi.org/10.1192/bjp.2020.241.
Key impacts of the interventions modelled in the study
For each intervention under assessment, the key impacts modelled
in the study, including clinical benefits, clinical harms, cost and cost
savings, are reported in Table 1. The impacts modelled in the study
were chosen based on importance and data availability, as informed
by published literature and expert opinion. Because of lack of evi-
dence about the adverse events of CBT and family interventions,
clinical harms were only modelled for antipsychotic medication.
Five adverse events were modelled for antipsychotic medications:
glucose intolerance, diabetes, weight gain, acute extrapyramidal
symptoms and neutropenia.
Input data
Four types of input data were used in our study: clinical evidence,
HRQoL, unit cost and healthcare resource use. A list of input data
for the schizophrenia WDM is reported in a previous publication.7
The key parameters that are most relevant to this study are reported
in Supplementary Table 2; these are briefly summarised below. The
current provision of CBT and family intervention were obtained
from the Early intervention in Psychosis national audit,2 which ana-
lysed data submitted by 55 mental health providers in England. A
recent systematic review11 identified two studies that reported dur-
ation of delay in initiating clozapine for patients with TRS in the
UK. The reported duration of delay ranges from 3.98 years in
Howes et al4 to 5 years in Najim et al.12 The result reported by
Howes et al was used in our study, becauseHowes et al was conducted
more recently than Najim et al, and has a larger sample size.4 The
clinical efficacy data of CBT, family intervention and CBT were
informed by published meta-analyses.1,13,14 HRQoL data were
obtained from published systematic reviews.1,15,16 Resource quan-
tities were mainly informed by the systematic reviews conducted by
the NICE schizophrenia guideline,17 new evidence identified from
rapid literature review conducted for this study and expert opinion
Jin et al
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where no evidence was identified. All costs were reported in 2016/
2017 UK Pound Sterling. Unit costs were obtained from the Unit
Costs of Health and Social Care 2017,18 prescription cost analysis
(England) 201719 and the NHS reference costs 2016–2017.20
Outcomes
The model estimates lifetime costs and lifetime QALYs gained for
patients referred to secondary care mental health services for pos-
sible psychosis. An annual discount rate of 3.5% was applied to
both costs and QALYs.10 To facilitate comparison between different
options, incremental cost-effectiveness ratios (ICERs) and incre-
mental net monetary benefit (NMB) were calculated by using the
estimates of costs and QALYs for each option assessed. The ICER
is calculated as the difference in cost between two competing
options, divided by the difference in QALYs. Cost-effectiveness is
usually assessed by comparing an ICER against a reference thresh-
old, which is intended to reflect the opportunity cost of displacing
one QALY elsewhere in the health system in order to fund the
new intervention. If the ICER falls below that threshold, the inter-
vention might be considered to represent a good use of health
resources, whereas if the ICER is above the threshold, the interven-
tion is likely to be considered cost-ineffective. NICE’s usual thresh-
old (λ) range for determining cost-effectiveness is £20 000–£30 000
per QALY gained for all interventions, except for life-extending
treatments for people who are at the end of their life (defined as
<24 months to live with current treatment) or for people with
very rare diseases. Incremental NMB is a transformation of the
ICER given some value of λ, which thereby reflects the monetary
value of any additional QALYs gained, less any additional costs (cal-
culated as ΔQALY×λ−ΔCost).
Sensitivity analysis
Three different types of sensitivity analyses were conducted to test
the robustness of our results under different input data and/or
assumptions: one-way sensitivity analysis, which assesses the
impact of changing the value of individual parameter; structural
sensitivity analysis, which assesses the impact of using alternative
assumptions of the model (e.g. whether CBT can prevent psychosis
or whether its effect is limited to delaying the transition from CHR
to psychosis); and probabilistic sensitivity analysis (PSA), which
assesses the joint impact of changing multiple input data simultan-
eously. In a PSA, each uncertain parameter is represented using a
pre-defined probability distribution. Using Monte-Carlo sampling
methods, each model run draws a random sample from each uncer-
tain parameter distribution. For this study, the process was repeated
5000 times, resulting in a distribution of cost and health outputs.
Results
The results of the base-case analysis are reported in Table 2 and
graphically presented in Fig. 2. As it shows in Table 2 and Fig. 2
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Fig. 1 Model structure. CBT, cognitive–behavioural therapy; CHR, clinical high risk of psychosis; FEP, first-episode psychosis.
Table 1 Key impacts of interventions considered in the schizophrenia whole-disease model
Interventions Clinical benefits Clinical harms Costs Cost savings
CBT for people at CHR Delaying transition
from CHR to
psychosis







None Cost of providing family
intervention






Adverse events, including acute EPS, weight
gain, glucose intolerance, diabetes and
neutropenia
Cost of antipsychotic medication




CBT, cognitive–behavioural therapy; CHR, clinical high risk of psychosis; FEP, first-episode psychosis; TRS, treatment-resistant schizophrenia; EPS, extrapyramidal symptoms.
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(a) and 2(b), full adherence to the NICE schizophrenia guideline
recommendations, for all three scenarios addressed, results in cost
savings and gains in QALYs. Of the three scenarios addressed, uni-
versal provision of family intervention for patients with FEP pro-
duces the largest gain in QALYs (0.0129 QALY per person),
whereas prompt provision of clozapine for patients with TRS pro-
duces the largest amount of cost savings (£4486 per person).
Fig. 2(c) presents the NMB of adherence to the NICE schizophrenia
guideline recommendations for all three scenarios addressed. For
both lower and higher thresholds of NICE (£20 000 and £30 000
per QALY, respectively), prompt provision of clozapine for patients
with TRS results in the greatest NMB, followed by universal provi-
sion of CBT for patients at CHR, and universal provision of family
intervention for patients with FEP.
The base-case conclusion for provision of CBT and clozapine
are robust to all one-way and structural sensitivity analyses
conducted (Supplementary File 1, Section 3). The base-case conclu-
sion for provision of family intervention is sensitive to the relative
risk of family intervention in delaying relapse of psychosis. When
the relative risk is increased from 0.63 to 0.83, increasing the provi-
sion of family intervention from 30.98 to 100% results in increased
costs and additional health gains, resulting in an ICER of £160 313
per QALY gained.
The PSA results are consistent with the base-case results: at a
£20 000 per QALY threshold, the probability of being cost-effective
compared with current practice is 0.74 for universal provision of
CBT, 0.65 for universal provision of family intervention and 0.96
for prompt provision of clozapine; and at a £30 000 per QALY
threshold, the probability of being cost-effective compared with
current practice is 0.75 for universal provision of CBT, 0.69 for uni-
versal provision of family intervention and 0.96 for prompt provi-
sion of clozapine.
Table 2 Base-case analysis results






(WTP=20 000 per QALY)
Ranking of NMB
(WTP=30 000 per QALY)
CBT for people at CHR
CBT (41.01% availability) 168 078 19.1904 – – Dominated 2 2
CBT (100.00% availability) 167 452 19.1904 −626 0.0000 Dominating 1 1
Family intervention for people with FEP
Family intervention (30.98% availability) 168 078 19.1904 – – Dominated 2 2
Family intervention (100.00% availability) 167 905 19.2033 −173 0.0129 Dominating 1 1
Clozapine for people with TRS
Clozapine (3.98-year delay) 168 078 19.1904 – – Dominated 2 2
Clozapine (no delay) 162 215 19.1977 −4486 0.0052 Dominating 1 1
QALY, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; WTP, willingness to pay; CBT, cognitive–behavioural therapy; CHR, clinical high risk
of psychosis; FEP, first-episode psychosis; TRS, treatment-resistant schizophrenia.









Topic A. Universal provision of CBT for patients at CHR
Topic B. Universal provision of family intervention for patients with an FEP
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Topic A. Universal provision of CBT for patients at CHR
Topic B. Universal provision of family intervention for patients with an FEP




Fig. 2 Net monetary benefit of adherence to topics A, B and C (per person). CBT, cognitive–behavioural therapy; CHR, clinical high risk of
psychosis; FEP, first-episode psychosis; NMB, net monetary benefit; QALY, quality-adjusted life-years; TRS, treatment-resistant schizophrenia;
WTP, willingness to pay.
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Discussion
Main findings and interpretation
The findings of this study suggest that adherence to the following
NICE recommendations are likely to decrease cost and improve
QALYs compared with the current practice, including: universal
provision of CBT to people at CHR, universal provision of family
intervention to people with FEP and prompt provision of clozapine
to people with TRS.
This is likely to be because the cost of adherence to the NICE
guideline recommendations (i.e. the cost of increasing provision
of CBT, family intervention and monitoring patients on clozapine)
is offset by the cost savings (i.e. delayed treatment cost of psychosis
because of use of CBT for people at CHR, reduced cost of treating
relapse for people with FEP, and reduced cost of treating relapse
for people with TRS because of use of clozapine).
Of the three scenarios addressed, increasing the provision of
family intervention from 30.98 to 100% produces the largest gain
in QALYs. This might be because, compared with the other two
scenarios, this intervention affects more patients. The target popu-
lation of the schizophrenia WDM relates to people referred to sec-
ondary care mental health services for possible psychosis. Of the
target population, the patient subgroup that can potentially
benefit from each scenario and its proportion in the target popula-
tion (based on the simulated outputs) is as follows: people at CHR
and who accept CBT (17.80%), people with FEP and who accept
family intervention (41.17%) and people with TRS (9.88%).
These results suggest that the proportion of the population that
can potentially benefit from universal provision of family interven-
tion is much larger than for the other two scenarios, which may
explain why adherence to the NICE recommendation for provision
of family intervention results in the greatest gains in QALYs. In
terms of costs, prompt provision of clozapine for patients with
TRS results in the greatest cost savings. This might be because
this scenario affects people with TRS and the cost of managing
people with TRS is 3 to 11 times higher than people with schizo-
phrenia who are not treatment resistant.21 Similarly, prompt provi-
sion of clozapine for patients with TRS results in the greatest NMB,
followed by universal provision of CBT for patients at CHR, and
universal provision of family intervention for patients with FEP.
To our knowledge, no similar analyses have been published that
compare the cost and health outcomes of different levels of imple-
mentation of the NICE schizophrenia guideline recommendations.
Therefore, it was not possible to compare the results of our analysis
with published literature. However, previous published economic
evaluation suggested that all three interventions assessed (CBT,
family intervention and clozapine) are cost-effective for people at
CHR or with a diagnosis of psychosis or schizophrenia.7
Therefore, increasing the provision or reducing delay in initiation
of those interventions are likely to decrease cost and improve
QALYs.
Implications for clinical practice
In the UK, although mental health disorders account for nearly a
quarter of the total disease burden, mental health services only
receives 13% of the total National Health Service budget.22
Further reductions in investments on mental health services have
been reported in recent years,23 which may compromise service
quality and affect patients’ health outcomes.24 The results of this
study show that one potential way to address the funding shortage
without compromising patient outcomes is to improve adherence to
the NICE schizophrenia guideline recommendations, as adherence
to all three recommendations addressed results in additional health
gains and cost savings. At the NICE willingness-to-pay thresholds of
£20 000 to 30 000 QALY gained, the areas prioritised for implemen-
tations are, in order of importance: prompt provision of clozapine to
people with TRS, universal provision of CBT for people at CHR and
universal provision of family intervention to people with FEP.
Strengths
Our study has five strengths. First, this study presents the first ana-
lysis that assesses cost and health outcomes of adherence to good
practice guidelines for schizophrenia. The results of this analysis
can help commissioners and service providers to identity ways to
improve outcomes while working within existing budgets. Second,
while the existing economic evidence only assessed the impacts of
adherence to one specific type of intervention (i.e. antipsychotic
medication),5 this study assessed the impacts of adherence to
three interventions within one analysis. The results of this study
can be used to directly compare the potential cost savings and
health benefits of improving implementation for different interven-
tions simultaneously, and thus help stakeholders to prioritise areas
of implementation when resources are scarce. Third, to prevent
overestimation of the benefits of adherence to the NICE guideline
recommendations, patient’s acceptance and adherence to interven-
tions were explicitly modelled. Thus, it was acknowledged that even
when CBT and family intervention are provided, they might not be
taken up by patients, and that people with TRS who are prescribed
with clozapine might discontinue clozapine for various reasons.
Fourth, the cost and health impacts of adverse events of anti-
psychotic medication were explicitly modelled. Five adverse
events were modelled, including acute extrapyramidal symptoms,
weight gain, glucose intolerance, diabetes and neutropenia.
Finally, the stability of our results under different assumptions
and different combinations of input data were tested with sensitivity
analyses.
Limitations
There are four limitations of this study. First, of the nine interven-
tions recommend by the NICE schizophrenia guideline, only three
were assessed within this study. The six interventions that were not
modelled were specialist mental health assessment, rapid triage
assessment of acute psychosis by the crisis resolution and home
treatment team, rapid tranquilisation, monitoring and treatment
for coexisting conditions, and occupational and educational inter-
ventions. The most common reason for excluding an intervention
from this analysis is lack of evidence about the clinical and cost
impacts of the intervention. Second, although the results of this ana-
lysis suggest that adherence to the NICE schizophrenia guideline
may reduce cost in the long term, the costs of improving adherence
are often incurred earlier, whereas expected cost savings may take
several years to be fully realised. This means at the early phases of
improving adherence to the NICE guideline recommendations,
commissioners may initially need to increase expenditures to
realise future cost savings; for example, employing therapists and
renting offices to provide CBT sessions. Third, not all patients
with TRS who are eligible for clozapine would be willing to initiate
clozapine. However, there is a lack of evidence about the acceptance
rate of clozapine in clozapine-naïve patients. Therefore, the original
acceptance rate of clozapine was assumed to be 100% in the model.
Finally, the study used to inform duration of delay in initiation of
clozapine was based on a cohort of patients commencing clozapine
in London between 2006 and 2010,4 because no better evidence was
identified. To our knowledge, there is a lack of evidence about the
duration of delay in initiating clozapine for patients with TRS in
other parts of the UK, and so the generalisability of the duration
of delay data used in our study is unknown.
NICE schizophrenia guideline adherence
5
Downloaded from https://www.cambridge.org/core. 08 Jan 2021 at 14:13:28, subject to the Cambridge Core terms of use.
Huajie Jin , PhD, King’s Health Economics, Institute of Psychiatry, Psychology &
Neuroscience, King’s College London, UK; Paul Tappenden, PhD, Health Economics and
Decision Science, School of Health and Related Research, University of Sheffield, UK;
James H. MacCabe , FRCPsych, Institute of Psychiatry, Psychology & Neuroscience,
King’s College London, UK; Stewart Robinson, PhD, School of Business and Economics,
Loughborough University, UK; Paul McCrone, PhD, Faculty of Education, Health and
Human Sciences, University of Greenwich, UK; Sarah Byford , PhD, King’s Health
Economics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London,
UK
Correspondence: Huajie Jin. Email: huajie.jin@kcl.ac.uk
First received 27 Mar 2020, final revision 24 Oct 2020, accepted 4 Nov 2020
Supplementary material
To view supplementary material for this article, please visit https://doi.org/10.1192/bjp.2020.
241.
Data availability
All data generated or analysed during this study are included in this published article and a pre-
vious publication about the methods of developing the schizophrenia whole-disease model.7
Author contributions
H.J. conducted the economic analysis, including adapting the existing schizophrenia for this
study, searching for and preparing input data, running the computer model and analysing
the results. J.H.M., P.T., S.R. and S.B. advised on the overall study design and analysis. J.H.M.
and P.M. helped with identification and selection of input data, and results interpretation.
H.J. led the writing of the paper. All authors edited the paper and approved the final version.
H.J. will serve as a guarantor for the overall content of the manuscript.
Funding
This work was supported by the Medical Research Council, UK (grant number MR/L011794/1 to
H.J., J.H.M. and P.M.).
Declaration of interest
J.H.M. received grants from HS Lundbeck outside the submitted work. The sponsor and funder
had no role in the design, data collection, analysis, interpretation, writing or publication of this
study. The views expressed are those of the authors and not necessarily those of the Medical
Research Council or HS Lundbeck. The other authors declare no competing interests.
ICMJE forms are in the supplementary material, available online at https://doi.org/10.1192/
bjp.2020.241.
References
1 National Institute for Health and Care Excellence (NICE). Psychosis and
Schizophrenia in Adults: Prevention and Management. Clinical Guideline
(CG178). NICE, 2014 (https://www.nice.org.uk/guidance/cg178).
2 NHS England. Report of the Early Intervention in Psychosis Audit. NHS England,
2016 (https://www.hqip.org.uk/resource/early-intervention-in-psychosis-
audit-report/#.X8eX2837SUk).
3 Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S, Bezborodovs
N, et al. What is the impact of mental health-related stigma on help-seeking? A
systematic review of quantitative and qualitative studies. Psychol Med 2015;
45(1): 11–27.
4 Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to
treatment guidelines in clinical practice: study of antipsychotic treatment prior
to clozapine initiation. Br J Psychiatry 2012; 201(6): 481–5.
5 Kashner TM, Rush AJ, Crismon ML, Toprac M, Carmody TJ, Miller AL, et al. An
empirical analysis of cost outcomes of the TexasMedication AlgorithmProject.
Psychiatr Serv 2006; 57(5): 648–59.
6 Jin H, Tappenden P, Robinson S, Achilla E, MacCabe JH, Aceituno D, et al. A
systematic review of economic models across the entire schizophrenia path-
way. Pharmacoeconomics 2020; 38(6): 537–55.
7 Jin H, Tappenden P, MacCabe JH, Robinson S, Byford S. Evaluation of the cost-
effectiveness of services for schizophrenia in the UK across the entire care
pathway in a single whole-disease model. JAMA Network Open 2020; 3(5):
e205888-e.
8 Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
statement. Pharmacoeconomics 2013; 31(5): 361–7.
9 Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and
utilities. Br Med Bull 2010; 96(1): 5–21.
10 National Institute for Health and Care Excellence (NICE). Developing NICE
Guidelines: The Manual. NICE, 2014 (https://www.nice.org.uk/media/default/
about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.
pdf).
11 Thien K, O’Donoghue B. Delays and barriers to the commencement of cloza-
pine in eligible people with a psychotic disorder: a literature review. Early
Interv Psychiatry 2019; 13(1): 18–23.
12 Najim H, Heath D, Singh P. Antipsychotic prescribing before clozapine in a
community psychiatric hospital: a case note review. Psychiatr Danub 2013; 25
(suppl 2): S165–70.
13 Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a
systematic review and meta-analysis. Psychol Med 2014; 44(3): 449–68.
14 Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al.
Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant
schizophrenia: a network meta-analysis. JAMA Psychiatry 2016; 73(3): 199–
210.
15 Fusar-Poli P, Rocchetti M, Sardella A, Avila A, Brandizzi M, Caverzasi E, et al.
Disorder, not just state of risk: meta-analysis of functioning and quality of life in
people at high risk of psychosis. Br J Psychiatry 2015; 207(3): 198–206.
16 Alshowkan A, Curtis J, White Y. Quality of life for people with schizophrenia: a
literature review. Arab J Psychiatry 2012; 23(2): 122–31.
17 National Institute for Health and Care Excellence (NICE). Psychosis and
Schizophrenia in Adults. NICE Guideline (CG178). NICE, 2014 (https://www.
nice.org.uk/guidance/cg178/evidence/full-guideline-490503565).
18 Curtis L. Unit Costs of Health & Social Care 2017. Personal Social Services
Research Unit, University of Kent, 2017 (https://www.pssru.ac.uk/project-
pages/unit-costs/unit-costs-2017/).
19 National Collaborating Centre for Nursing and Supportive Care. Violence: The
Short-Term Management of Disturbed/Violent Behaviour in In-Patient
Psychiatric Settings and Emergency Departments. Royal College of Nursing
(UK), 2005.
20 Department of Health. NHS Reference Costs 2016 to 2017. Department of
Health, 2017 (https://improvement.nhs.uk/resources/reference-costs/).
21 Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and eco-
nomic burden of treatment-resistant schizophrenia: a systematic literature
review. Int Clin Psychopharmacol 2014; 29(2): 63–76.
22 Centre for Economic Performance’s Mental Health Policy Group. How Mental
Illness Loses Out in the NHS. London School of Economics and Political
Science, 2012 (http://eprints.lse.ac.uk/44572/).
23 McNicoll A. Mental Health Trust Funding Down 8% from 2010 Despite
Coalition’s Drive for Parity of Esteem. Campaign to Save Mental Health
Services in Norfolk & Suffolk, 2015 (https://www.communitycare.co.uk/2015/
03/20/mental-health-trust-funding-8-since-2010-despite-coalitions-drive-par-
ity-esteem/).
24 Docherty M, Thornicroft G. Specialist mental health services in England in




Downloaded from https://www.cambridge.org/core. 08 Jan 2021 at 14:13:28, subject to the Cambridge Core terms of use.
